
Base to Base biotech podcast 8: ‘Photoshop for proteins’ and improving operations
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
Acerca de esta escucha
This week on the podcast, we have a conversation with Elise de Reus, the co-founder of Cradle, a biotech startup that is revolutionising protein design, and a chat about improving hospital operations with Proximie’s CEO and founder, plastic surgeon Dr. Nadine Hachach-Haram.
Interview times:
01:55 Proximie
21:40 Cradle
Proximie
Proximie has built the only cloud OS for intelligent operating rooms. With 800 operating rooms across the US and UK utilizing Proximie, the company is rapidly growing its US footprint leveraging its connected surgical platform to drive operational efficiency.
With Proximie, medical devices and operating rooms are connected, smart, and secure. Information flows in and out of the OR in real time.
Proximie's platform, with extended AI agents, provides real-time data across the perioperative surgical pathway, including advanced scheduling modules. The company is growing and securing market share in the competitive US healthcare landscape, fuelled by strategic partnerships with medtech leaders like Olympus and Distal Motion.
Cradle
Cradle is a biotech startup that is revolutionising protein design. It leverages genAI to optimise proteins for animal-free food, better medicines, and sustainable materials.
Machine learning-generated sequences are transformed into physical proteins.
Despite being founded in 2021, Cradle, founded in 2021, closed a $73m series B last year, and already works with more than 20 biotech companies, including industry giants like Novo Nordisk, Johnson & Johnson Innovative Medicine, Novozymes, and Grifols.
Cradle’s AI prioritises language-based models over structure-based ones, enabling better predictions of protein function, stability, and degradation in real-world conditions.
its AI-designed protein binds to its target 8 times more tightly than a leading cancer therapeutic. It accelerates early-stage research for clinical trials by 1.5x to 12x.
To ensure accuracy, Cradle also operates a wet lab to generate real-world validation data.
To get in touch with guest suggestions, please email jim@deeptechdigest.com